News & Events

Are we going too fast with checkpoint inhibitors?

A recent clinical trial for a cancer immunotherapy drug from the biotech company Incyte failed, surprising many observers. Since then, a new editorial in Science notes, three companies have canceled, suspended, or downsized 12 other phase III trials of the compound, epacadostat, or two similar drugs.

Why to build up Neander-Brains ?

The researchers plan to compare the Neanderthalized organoids to fully human ones to assess the speed at which the stem cells divide, develop, and organize into three-dimensional brain structures and whether the brain cells are wired differently

Roche’s immunotherapy combo receives FDA priority review

The US Food and Drug Administration (FDA) has granted Roche priority review for Tecentriq (atezolizumab), in combination with Avastin (bevacizumab​), paclitaxel and carboplatin (chemotherapy), as a first-line treatment for metastatic non-squamous non-small cell lung cancer (NSCLC).

Virtual clinical trials will be standard, says THREAD exec on Novartis project

Last month, Novartis announced​ the development of the new app that aims to allow researchers to track ophthalmic disease progression by collecting patients’ real-time data.

WuXi AppTec IPO tops $353m

WuXi AppTec’s​ initial public offering (IPO) of 104,198,600 shares of common stock was offered on the Shanghai Stock Exchange​ at RMB21.60 per share.

Most academic institutions not prepared to meet new trial regulations known as the final rule

The study, published in the journal BMC Medicine​​, details survey data from more than 350 US academic institutions that conduct clinical trials. “Relatively few” reportedly had the staff or policies needed to comply with the new requirements by the US Department of Health and Human Services (HHS) and National Institutes of Health (NIH) for clinical trial registration and reporting

Worldwide and Datavant tackling neurodegenerative study design in new partnership

To address the challenges of clinical research in neurodegenerative diseases, the Morrisville, NC-based contract research organization (CRO) Worldwide Clinical Trials has announced a partnership with Datavant aimed at enhancing clinical trials methodologies and algorithms.

AstraZeneca announces EU approval of Lynparza for ovarian cancer

AstraZeneca and Merck have announced the approval of Lynparza (olaparib) tablets by the European Medicines Agency (EMA) to treat platinum-sensitive relapsed ovarian cancer.

The future of the small molecule? Increased complexity and biologic pairings, says industry

According to the contract development and manufacturing organisation (CDMO) executive, approximately 8,000 small molecule products are currently active in research and development – marking a 25% growth over the past two years.

Get in touch

Subscribe to Eclosion Newsletter


© 2016 Fondation Eclosion
All rights reserved
Webdesign: Comstone / Pierre Chassany
WordPress Development: Olivier Gisiger